



**California State Board of Pharmacy**  
2720 Gateway Oaks Drive, Suite 100  
Sacramento, CA 95833  
Phone: (916) 518-3100 Fax: (916) 574-8618  
www.pharmacy.ca.gov

Business, Consumer Services and Housing Agency  
Department of Consumer Affairs  
Gavin Newsom, Governor



**Notice of Meeting and Agenda**  
**Teleconference Legislation and Regulation Committee Meeting**

DATE & TIME: July 18, 2022, 1:00 p.m.

NOTE: Pursuant to the provisions of Government Code section 11133, neither a public location nor teleconference locations are provided.

**INSTRUCTIONS FOR OBSERVATION:**

WEBCAST: <https://thedcapage.blog/webcasts> Webcast will be available at 1:00 p.m. on July 18, 2022.

**FOR PUBLIC COMMENT, PLEASE LOG ON TO THIS WEBSITE**

**FOR PUBLIC PARTICIPATION AND COMMENT FROM A REMOTE LOCATION, PLEASE LOG ON TO WEBEX:** To access the WebEx event, attendees will need to click the following link and enter a first name, last name, email, and the event password listed below:

<https://dca-meetings.webex.com/dca-meetings/j.php?MTID=md823b030863d9d93179003102fd02a0c>

*If joining using the link above*

Webinar number: 2494 036 4994

Webinar password: CSBP07182022

*If joining by phone*

+1-415-655-0001 US Toll

Access code: 249 403 64994

Passcode: 27270718

Members of the public participating via WebEx will be able to hear the meeting and provide public comment but may not be able to observe the meeting. The preferred audio connection is via phone bridge. The phone number and access code will be provided as part of your connection to the meeting. General instructions for using WebEx can be found at the end of the agenda.

Members of the public may but are not obligated to provide their names or personal information as a condition of observing or participating in the meeting. When signing into the WebEx platform, participants may be asked for their name and email address. Participants who choose not to provide their names will need to provide a unique identifier such as their initials or another alternative, so that the meeting moderator can identify individuals who wish to make public comment; participants who choose not to provide their email address may utilize a fictitious email address in the following sample format: [XXXXX@mailinator.com](mailto:XXXXX@mailinator.com).

**FOR OBSERVATION ONLY:**

WEBCAST: The Committee plans to webcast this meeting on the Department of Consumer Affairs' website at <https://thedcapage.blog/webcasts>. Webcast will be available the earliest at 1:00 p.m. on July 18, 2022. Using the Webcast link will allow only for observation with closed captioning. Webcast availability cannot, however, be guaranteed due to resource limitations or technical difficulties. The meeting will not be cancelled if Webcast is unavailable. If you wish to participate, please plan to participate via the WebEx option listed above.

**Important Notices to the Public:** The Legislation and Regulation Committee will hold a teleconference meeting via WebEx – access information is provided above. General instructions for using WebEx are attached to the agenda. The meeting is open to the public and is accessible to the physically disabled. A person who needs a disability-related accommodation or modification in order to participate in the meeting may make a request by contacting Debbie Damoth at (916) 518-3090, by emailing [Debbie.Damoth@dca.ca.gov](mailto:Debbie.Damoth@dca.ca.gov) or sending a written request to the Board of Pharmacy, 2720 Gateway Oaks Drive, Suite 100, Sacramento CA 95833. Providing your request at least five business days before the meeting will help to ensure availability of the requested accommodation.

The time and order of agenda items are subject to change at the discretion of the Committee Chair. In the event a quorum of the committee is unable to attend the meeting, or the Committee is unable to maintain a quorum once the meeting is called to order, the members present may, at the chair’s discretion, continue to discuss items from the agenda and make recommendations to the full board at a future meeting.

Government Code section 11125.7 provides the opportunity for the public to address each agenda item during discussion or consideration by the committee or prior to the Committee taking any action on said item. Members of the public will be provided appropriate opportunities to comment on any issues before the committee, but the Chair may, at his or her discretion, apportion available time among those who wish to speak. If public comment is not specifically requested, members of the public should feel free to request an opportunity to comment. Individuals may appear before the Committee to discuss items not on the agenda; however, the Committee can neither discuss nor take official action on these items at the time of the same meeting (Government Code sections 11125, 11125.7(a)).

## Agenda

### Discussion and action may be taken on any agenda item.

July 18, 2022

Call to Order

1:00 p.m.

- I. Call to Order, Establishment of Quorum, and General Announcements
- II. Public Comments on Items Not on the Agenda/Agenda Items for Future Meetings  
*Note: The Committee may not discuss or take action on any matter raised during this public comment section that is not included on this agenda, except to decide whether to place the matter on the agenda of a future meeting. [Government Code sections 11125, 11125.7(a)]*
- III. Approval of April 26, 2022, Committee Meeting Minutes
- IV. Discussion and Consideration of Pending Legislation Impacting the Practice of Pharmacy, the Board’s Jurisdiction or Board Operations
  1. Assembly Bill 852 (Wood) Health Care Practitioners: Electronic Prescriptions: Nurse Practitioner Scope of Practice: Practice without Standardized Procedures
  2. Assembly Bill 1328 (Irwin) Clinical Laboratory Technology and Pharmacists
  3. Assembly Bill 1662 (Gipson) Licensing Boards: Disqualification from Licensure: Criminal Conviction

4. Assembly Bill 1733 (Quirk) State Bodies: Open Meetings
5. Assembly Bill 2194 (Ward) Pharmacists and Technicians; Continuing Education: Cultural Competency
6. Senate Bill 731 (Durazo) Criminal Records: Relief
7. Senate Bill 872 (Dodd) Pharmacies: Mobile Units
8. Senate Bill 988 (Hueso) Compassionate Access to Medical Cannabis Act or Ryan’s Law
9. Senate Bill 1237 (Newman) Licenses: Military Service
10. Senate Bill 1259 (Laird) Pharmacists: Furnishing Opioid Antagonists
11. Senate Bill 1346 (Becker) Surplus Medication Collection and Distribution

V. Discussion and Consideration of Board Adopted Regulations Undergoing Final Review by the Office of Administrative Law

1. Proposed Regulation to Amend Title 16, CCR Section 1715.65 Related to Inventory Reconciliation
2. Proposed Regulation to Amend Title 16, CCR Section 1708.1 Related to the Temporary Closure of Facilities

VI. Discussion and Consideration of Board Adopted Regulations Undergoing Final Review by the Department of Consumer Affairs or Business, Consumer Services and Housing Agency

1. Proposed Regulations to Amend Title 16, CCR Section 1715 to Update Self-Assessment Forms 17M-13 and 17M-14
2. Proposed Regulation to Amend Title 16, CCR Section 1784 to Update the Wholesale/3PL Self-Assessment Form 17M-26
3. Proposed Regulations to Amend Title 16, CCR Section 1793.5 Related to Pharmacy Technician Application, Section 1793.6 Related to the Pharmacy Technician Training Requirements, and Section 1793.65 Related to the Pharmacy Technician Certification Programs

VII. Discussion and Consideration of Board Approved Regulations Undergoing Pre-Notice Review by the Department of Consumer Affairs or Business, Consumer Services and Housing Agency

1. Proposed Regulation to Amend Title 16 CCR Section 1707.6 Related to the Notice to Consumers
2. Proposed Regulation to Amend Title 16, CCR Section 1709.1, Related to the Designation of Pharmacist-in-Charge
3. Proposed Regulation to Amend Title 16, CCR Section 1715.1 Related to the ADDS Self-Assessment Form 17M-112
4. Proposed Regulation to Amend Title 16, CCR Section 1760 Related to the Disciplinary Guidelines

VIII. Discussion and Consideration of Committee’s Strategic Plan Goals

IX. Future Committee Meeting Dates

X. Adjournment

Upon conclusion of business